700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Original Articles Open Access
Multidrug-resistant tuberculosis (MDR-TB) caused by mycobacterium tuberculosis becomes a global life threatening issue in many developing countries including India. Treatment of MDR-TB with second line anti tubercular drugs is associated with lot of side effects which includes hepatitis, depression and hallucinations. Siddha system of medicine has wide choice of therapeutic formulations which offers ailment against dreadful infectious like TB.As an objective of exploring alternate therapy for the clinical management of MDR-TB with less or no side effects the present investigation aimed at evaluating the anti-mycobacterial activity of the siddha drug Singi Chenduram (SC) using Luciferase Reporter Phage assay. In-vitro anti-mycobacterial activity evaluation of SC carried out at the concentration of 100 and 500μg/ml against standard strains of M. tuberculosis H37Rv, clinical isolates of M. tuberculosis strains resistant to first line anti-TB drugs (Streptomycin (S), Isoniazid (H), Rifampicin (R) and Ethambutol (E)) in comparison with marketed standard Rifampicin 2μg/ml. The result obtained from the study clearly reveals that the drug SC at both the concentration of 100 and 500μg/ml shows significant percentage reduction in relative light units (RLU) which is a marker indication of its efficacy against. Hence form the study it was concluded that the drugs like SC from the siddha system of Indian traditional medicine will provides clinically significant results in treating MDR-TB and further has to be ascertained by proper clinical evaluation in the infected subjects.
To read the full article Peer-reviewed Article PDF
Author(s): K Rajamaheswari M Pitchiah Kumar K Arunachalam
MDR-TB, Singi Chenduram, Siddha drug, Luciferase Reporter Phage assay, M. tuberculosis H37Rv, Rifampicin, Anti-Mycobacterial